HENDERSON, Nev. - Zura Bio Limited (NASDAQ:ZURA) announced that the design of its Phase 2 TibuSURE clinical trial has been accepted for poster presentation at the Systemic Sclerosis World Congress ...
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and ...
A live webcast of the Leerink Global Healthcare Conference fireside chat will be available in the Investors section of the Company's website under News & Events. A replay will be accessible for at ...
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients ...
Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with ...
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The Company’s pipeline includes product ...
— We have everything you need: full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results